Indoramin HCl | CAS#38821-52-2

MedKoo Cat#: 535031 | Name: Indoramin HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Indoramin is a piperidine antiadrenergic agent. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action. Indoramin works by blocking the action of certain nerve impulses. This blocking action is useful in two different medical conditions. It is used to help control the symptoms of prostate gland enlargement, and it also reduces blood pressure in people with high blood pressure (hypertension).

Chemical Structure

Indoramin HCl

CAS#38821-52-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 535031

Name: Indoramin HCl

CAS#: 38821-52-2 (HCl)

Chemical Formula: C22H26ClN3O

Exact Mass: 383.1764

Molecular Weight: 383.92

Elemental Analysis: C, 68.83; H, 6.83; Cl, 9.23; N, 10.95; O, 4.17

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 450.00	2 Weeks
50mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

38821-52-2 (HCl) 26844-12-2 (free base)

Synonym

Indoramin HCl; Doralese; Indoramin hydrochloride; Vidora; Wy 21901 HCl; Wydora; Wypres; Wypresin;

IUPAC/Chemical Name

Benzamide, N-(1-(2-(1H-indol-3-yl)ethyl)-4-piperidinyl)-, monohydrochloride

InChi Key

AFJSFHAKSSWOKG-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H25N3O.ClH/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21;/h1-9,16,19,23H,10-15H2,(H,24,26);1H

SMILES Code

O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 383.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Villa AF, Tran Hong H, Lee HM, Chataigner D, Garnier R. Acute indoramin poisoning: a review of 55 cases reported to the Paris Poison Centre from 1986 t o 2010. Therapie. 2012 Nov-Dec;67(6):523-7. doi: 10.2515/therapie/2012075. Epub 2012 Dec 19. PMID: 23249578. 2: Nisse P, Soubrier S, Saulnier F, Mathieu-Nolf M. Torsade de pointes: a severe and unknown adverse effect in indoramin self-poisoning. Int J Cardiol. 2009 Apr 3;133(2):e73-5. doi: 10.1016/j.ijcard.2007.11.029. Epub 2008 Jan 9. PMID: 18191476. 3: Pitt J, Dawson PM, Hallan RI, Boulos PB. A double-blind randomized placebo- controlled trial of oral indoramin to treat chronic anal fissure. Colorectal Dis. 2001 May;3(3):165-8. doi: 10.1046/j.1463-1318.2001.00227.x. PMID: 12790983. 4: Sengupta S, Cooney R, Baj M, Ni'Muircheartaigh R, O'Donnell LJ. Prokinetic effect of indoramin, an alpha-adrenergic antagonist, on human gall-bladder. Aliment Pharmacol Ther. 2002 Oct;16(10):1801-3. doi: 10.1046/j.1365-2036.2002.01337.x. PMID: 12269974. 5: Pupo AS, Cavenaghi DL, Campos M, Lucena Morais P, Jurkiewicz NH, Jurkiewicz A. Effects of indoramin in rat vas deferens and aorta: concomitant alpha1-adrenoceptor and neuronal uptake blockade. Br J Pharmacol. 1999 Aug;127(8):1832-6. doi: 10.1038/sj.bjp.0702735. PMID: 10482913; PMCID: PMC1566180. 6: Watson AJ, Currie I, Jarvis GJ. A prospective placebo controlled double blind randomised study to investigate the use of indoramin to prevent post-operative voiding disorders after surgical treatment for genuine stress incontinence. Br J Obstet Gynaecol. 1999 Mar;106(3):270-2. doi: 10.1111/j.1471-0528.1999.tb08242.x. PMID: 10426648. 7: Farrell AM, Bunker CB. Cutaneous eruption due to indoramin. Clin Exp Dermatol. 1998 Sep;23(5):233. doi: 10.1046/j.1365-2230.1998.00309.x. PMID: 10233611. 8: Pradalier A, Vincent D, Barzegar C. Hyper-prolactinémie induite par l'indoramine [Hyperprolactinemia induced by indoramin]. Therapie. 1998 Sep- Oct;53(5):500-2. French. PMID: 9921044. 9: Lloyd SN, McMahon A, Muller W, Buckley JF, Deane RF, Kirk D, Kyle KF. Is indoramin an effective alternative to prostatectomy? Br J Urol. 1992 Oct;70(4):408-11. doi: 10.1111/j.1464-410x.1992.tb15798.x. PMID: 1450850. 10: James MA, Jones JV. Anti-arrhythmic properties of the alpha-adrenoceptor blocking drug indoramin. Br J Clin Pharmacol. 1991 Sep;32(3):375-8. doi: 10.1111/j.1365-2125.1991.tb03915.x. PMID: 1685666; PMCID: PMC1368534. 11: Stott MA, Abrams P. Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol. 1991 May;67(5):499-501. doi: 10.1111/j.1464-410x.1991.tb15194.x. PMID: 1710162. 12: Gagało I, Szreder Z. The effect of doxazosin, urapidil and indoramin pretreatment on fever produced by E. coli lipopolysaccharide in rabbits. Gen Pharmacol. 1991;22(5):923-7. doi: 10.1016/0306-3623(91)90231-t. PMID: 1684772. 13: Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634. PMID: 1981634. 14: Anthony J, Rees AE, Davey DA. Indoramin in the treatment of pregnancy hypertension. A placebo-controlled trial comparing the efficacy of indoramin with alpha-methyldopa. S Afr Med J. 1990 Oct 20;78(8):458-61. PMID: 2218781. 15: Schabort I, Odendaal HJ, Pierce DM. The pharmacokinetics of oral indoramin during pregnancy. Br J Clin Pharmacol. 1990 Apr;29(4):397-401. doi: 10.1111/j.1365-2125.1990.tb03656.x. PMID: 2328193; PMCID: PMC1380108. 16: Muller CA, Worthington MG, Thandroyen FT. Antiarrhythmic and metabolic effects of indoramin during acute regional ischemia and reperfusion in isolated rat heart. J Cardiovasc Pharmacol. 1990 Mar;15(3):408-13. doi: 10.1097/00005344-199003000-00010. PMID: 1691364. 17: Chow W, Hahn D, Sandhu D, Slaney P, Henshaw R, Das G, Wells P. Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br J Urol. 1990 Jan;65(1):36-8. doi: 10.1111/j.1464-410x.1990.tb14657.x. PMID: 1690068. 18: Abrams SM, Pierce DM, Johnston A, Hedges A, Franklin RA, Turner P. Pharmacokinetic interaction between indoramin and ethanol. Hum Toxicol. 1989 May;8(3):237-41. doi: 10.1177/096032718900800306. PMID: 2744781. 19: Bennett JM, Weich DJ, Schoeman HS. Double-blind study comparing indoramin and propranolol in the treatment of black patients with hypertension. S Afr Med J. 1988 Dec 17;74(12):619-21. PMID: 3061032. 20: Niveditha Y, Bishop N, Boyle RM, Stoker JB, Mary DA. Changes in myocardial ischaemia during isosorbide dinitrate or indoramin therapy in patients with stable angina using relations between the ST segment and heart rate. Int J Cardiol. 1988 Jun;19(3):341-54. doi: 10.1016/0167-5273(88)90239-2. PMID: 3294190.